Astral Systems
Bristol-based deep-tech company developing modular multi-state fusion reactors that run several fusion reactions in parallel rather than one large tokamak.
Last refreshed: 14 July 2026 · Appears in 1 active topic
Can fusion hardware solve the UK's medical radioisotope shortage before 2027?
Timeline for Astral Systems
Mentioned in: Five seed rounds stir beneath megadeals
UK Startups and InnovationRaised a GBP23m Series A to commercialise modular fusion reactors
UK Startups and Innovation: Astral raises GBP23m for modular fusionWhat does Astral Systems make?
Who invested in Astral Systems' Series A?
Why does Astral Systems use nuclear fusion?
Background
Astral Systems closed a GBP23 million Series A in June 2026 to scale production of medical radioisotopes used in cancer diagnosis and therapy, led by Mercia Ventures and Tees River with Daphni, Speedinvest and Playfair Capital.
Founded in Bristol in 2021 by Charles Firestone and Dr Tom Wallace-Smith, the company builds modular multi-state fusion reactors that run several smaller reactions in parallel rather than chasing one large tokamak. Several reactors already operate at Technology Readiness Level 9, having generated over GBP3 million in research-contract revenue, and the new capital funds a scale-up facility at the former Berkeley Power Station site in Gloucestershire.
The approach targets a persistent shortage of isotopes such as Actinium-225 and Lead-212, which are increasingly used in targeted cancer therapies with few reliable production sources. Astral is working with McMaster University and Brazil's Institute for Energy and Nuclear Research to bring an isotope to market by early 2027, treating fusion hardware as a medical-supply tool rather than a future power source.
